◂ RESEARCH LIBRARY
Eloralintide research peptide

Research Overview

Eloralintide

LY3841136 — lipidated selective amylin-receptor agonist peptide

CoA on requestPurity CoAResearch use only

In 60 seconds

Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist.

  • Describes eloralintide’s discovery and pharmacology through to clinical proof of concept.
  • A phase 1 study characterised eloralintide’s pharmacokinetics, tolerability and early body-weight effects.
  • Over 48 weeks, mean body-weight reductions of 9.5% to 20.1% were reported across eloralintide doses versus 0.4% with placebo.

OVERVIEW

Eloralintide (LY3841136 — lipidated selective amylin-receptor agonist peptide) is a research-grade peptide supplied by Living Water Labs for laboratory investigation. Selective, long-acting amylin-receptor agonist (LY3841136) — 15 mg lyophilised powder per vial.. Each published certificate is an independent Janoshik Analytical report naming the compound and its HPLC purity; certificates not yet published can be requested. The summary below outlines documented mechanisms and study areas reported in the research literature.

Scientific name

LY3841136 — lipidated selective amylin-receptor agonist peptide

Vial size

15mg

DOCUMENTED RESEARCH AREAS

  • ▸Investigational selective, long-acting amylin-receptor agonist (Eli Lilly)
  • ▸Amylin acts on brain satiety circuits and slows gastric emptying
  • ▸Phase 1 proof of concept and discovery data published 2025–2026
  • ▸48-week phase 2 trial published in The Lancet (2025)
  • ▸15 mg lyophilised vial — laboratory research use only

MECHANISM OF ACTION

Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist. Amylin is a pancreatic hormone co-secreted with insulin that acts on brain satiety circuits and slows gastric emptying; eloralintide was engineered for selective amylin-receptor activity with a profile suited to once-weekly dosing in trials.

  • ▸Selective, long-acting amylin-receptor agonist
  • ▸Amylin acts on hindbrain satiety circuits and slows gastric emptying
  • ▸Investigational — phase 1 and phase 2 data published 2025–2026

STUDY SUMMARIES

4 peer-reviewed references

Mol Metab · 2025

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

Describes eloralintide’s discovery and pharmacology through to clinical proof of concept.

View on PubMed (PMID 41109426)

Diabetes Obes Metab · 2026

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

A phase 1 study characterised eloralintide’s pharmacokinetics, tolerability and early body-weight effects.

View on PubMed (PMID 41559929)

Lancet · 2025

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Over 48 weeks, mean body-weight reductions of 9.5% to 20.1% were reported across eloralintide doses versus 0.4% with placebo.

View on PubMed (PMID 41207310)

Diabetes Obes Metab · 2026

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials

Reviews experimental and early-phase clinical data across amylin analogues, including eloralintide.

View on PubMed (PMID 42452898)

CITATIONS

  1. 1.Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. PMID 41109426. pubmed.ncbi.nlm.nih.gov/41109426
  2. 2.Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026. PMID 41559929. pubmed.ncbi.nlm.nih.gov/41559929
  3. 3.Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. PMID 41207310. pubmed.ncbi.nlm.nih.gov/41207310
  4. 4.Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. PMID 42452898. pubmed.ncbi.nlm.nih.gov/42452898

Citations describe findings reported in the referenced preclinical, in-vitro or clinical literature. They are provided for research and educational purposes only and are not a therapeutic claim.

EXPLORE VARIANTS Back to Library
Look up a purity CoAHow-to guidesReconstitution toolGlossary

Research Tool

Peptide Reconstitution Calculator

Concentration, draw volume & syringe units in seconds.

All information is provided for research and educational purposes only and describes findings in preclinical/in-vitro literature. Not medical advice. Products are supplied strictly for research purposes — not for human consumption.

Related Research & Reading

Keep exploring — goal collections, plain-language guides and the wellness journal, all in one place.

Research Axes · 22 Goals

Shop by Goal

Start from what you want to change rather than from a compound name. Every goal below opens a full vertical — what the research points to, what we stock for it, and how to run it.

Browse all goals →

Health & Longevity

Systemic wellness — the compounds most studied for how you age, recover overnight and feel day to day.

Performance & Repair

Training, recovery and tissue-repair research — for getting back to the gym, the field or the trail sooner.

By Concern

Start from what you want to change — skin, hair, focus, mood, libido — and see what research points to.

Who It’s For

Curated entry points for specific researchers — women, veterinary work, first-timers and bulk buyers.

HPLC tested · Janoshik · Janoshik Certificates · Nationwide Delivery